Compare COFS & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COFS | TRDA |
|---|---|---|
| Founded | 1898 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 443.5M | 481.6M |
| IPO Year | 1995 | 2021 |
| Metric | COFS | TRDA |
|---|---|---|
| Price | $27.90 | $11.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $36.00 | $20.00 |
| AVG Volume (30 Days) | 79.7K | ★ 196.2K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.22% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.01 | N/A |
| Revenue | ★ $227,624,000.00 | $25,421,000.00 |
| Revenue This Year | $21.87 | $39.97 |
| Revenue Next Year | $4.47 | $53.29 |
| P/E Ratio | $13.61 | ★ N/A |
| Revenue Growth | ★ 63.64 | N/A |
| 52 Week Low | $24.89 | $4.93 |
| 52 Week High | $33.58 | $13.99 |
| Indicator | COFS | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 45.08 | 45.25 |
| Support Level | $26.10 | $9.78 |
| Resistance Level | $30.76 | $12.56 |
| Average True Range (ATR) | 1.00 | 0.87 |
| MACD | 0.00 | -0.21 |
| Stochastic Oscillator | 38.40 | 15.87 |
ChoiceOne Financial Services Inc is a full-service banking institution. It is engaged in the business of providing personal and business banking solutions, borrowing solutions, and treasury notes and bonds services. The bank's product and services portfolio consist of time, savings and demand deposits, safe deposit services, automated transaction machine services, commercial and consumer loans, commercial lending to business, industry, agricultural, construction, inventory, and real estate categories. Its primary market area is Kent, Muskegon, Newaygo, and Ottawa counties in western Michigan, and Lapeer, Macomb, and St. Clair counties in southeastern Michigan in the communities where the Bank's respective offices are located.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.